As it is widely known, smoking is the leading cause of lung cancer. According to the Centers for Disease Control and Prevention (CDC), smokers are 15 to 30 times more likely to develop lung cancer than nonsmokers. However, quitting smoking is a difficult task. Due to the addictive nature of smoking, 52-63% of lung cancer patients continue to smoke even after being diagnosed.
There is controversy within the medical community about whether or not vaping can reduce the risk of lung cancer by inducing smoking cessation.
On the 8th of this month, the World Lung Cancer Association held a heated debate on the effectiveness of e-cigarettes in helping smokers quit. Lung cancer clinical physician Matthew Avison, who has treated hundreds of lung cancer patients in clinical trials, stated that "hundreds of chemicals will enter the body during the process of smoking tobacco. Patients struggling to quit smoking need an alternative." He believes that "a principle of not burning tobacco but vaporizing liquid makes it easy to understand that e-cigarettes are less harmful." Avison continued by referencing a study that found e-cigarette users who switched from traditional smoking had quit smoking for at least 6 months. He believes that this should be seriously considered as an alternative method for smoking cessation.
However, there are also opposing views. Emily Stone, a professor at St Vincent Hospital in Sydney, expressed in a discussion on the same day, "The effect of e-cigarettes on smoking cessation varies depending on the research methods. The fact is," she said. Professor Stone stated, "E-cigarettes contain fewer toxic substances than tobacco cigarettes, but the risk is at an uncertain level.
Statement:
This article is compiled from third-party information and is intended for industry communication and learning purposes only.
This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the content. The compilation of this article is only intended for internal industry communication and research.
Due to limitations in the level of translation, this article may not fully convey the same meaning as the original text. Please refer to the original text for accuracy.
2FIRSTS aligns completely with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions.
The copyright of compiled information belongs to the original media and author(s). If there is any infringement, please contact us for removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
